Avacincaptad pegol 2 mg for Macular Degeneration

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Retina Foundation of the Southwest, Dallas, TX
Macular Degeneration+2 More
Avacincaptad pegol 2 mg intravitreal injection - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Eligible Conditions

  • Macular Degeneration
  • Geographic Atrophy

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Macular Degeneration

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Month 18

Month 18
Adverse Events

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Macular Degeneration

Trial Design

1 Treatment Group

Avacincaptad pegol 2 mg
1 of 1
Experimental Treatment

400 Total Participants · 1 Treatment Group

Primary Treatment: Avacincaptad pegol 2 mg · No Placebo Group · Phase 3

Avacincaptad pegol 2 mg
Drug
Experimental Group · 1 Intervention: Avacincaptad pegol 2 mg intravitreal injection · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 18
Closest Location: Retina Foundation of the Southwest · Dallas, TX
Photo of Dallas  1Photo of Dallas  2Photo of Dallas  3
2014First Recorded Clinical Trial
16 TrialsResearching Macular Degeneration
23 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female patient aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment.
You must provide new written informed consent for this OLE trial prior to participation.
You must be able to return for all trial visits for the duration of the 18-month trial.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.